Vivani Medical Inc (VANI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.07+1.90%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VANI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
"We enrolled and dosed all 20 SLIM-1 participants ahead of schedule, with every insertion procedure completed successfully.
Stated in 2 of 2 supplied quarters. Management reported: “"We enrolled and dosed all 20 SLIM-1 participants ahead of schedule, with every insertion procedure completed successfully.” “Top-line data from SLIM-1 are expected in November 2026, which the Company anticipates will pave the way for initiation of a Phase 2 dose-ranging trial in 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“"We enrolled and dosed all 20 SLIM-1 participants ahead of schedule, with every insertion procedure completed successfully.”
“Based on our prior experience with the execution of our first-in-human LIBERATE-1 clinical trial in 2025, we anticipate top-line SLIM-1 results by the end of this year.”
Also in July 2026, Vivani announced that its wholly owned subsidiary Cortigent, Inc., a developer of brain-computer interface devices based on precision neurostimulation technology, entered into a de…
Stated in 2 of 2 supplied quarters. Management reported: “Also in July 2026, Vivani announced that its wholly owned subsidiary Cortigent, Inc., a developer of brain-computer interface devices based on precision neurostimulation technology, entered into a definitive merger agreement with Nasdaq-listed ClearOne, Inc. The transaction, which is expected to close in the third quarter of 2026 subject to customary closing conditions, is designed to establish Cortigent as a separately listed public company, reduce Vivani's direct expenditures related to Cortigent, and enable the Vivani team to focus fully on advancing its portfolio of miniature, ultra long-acting drug implants.”
“Also in July 2026, Vivani announced that its wholly owned subsidiary Cortigent, Inc., a developer of brain-computer interface devices based on precision neurostimulation technology, entered into a de…”
“Transition of Cortigent into an independent, publicly traded company.”
Second Quarter 2026 Financial Results Cash : As of June 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $ 20.8 million, compared to $ 17.6 million as of December 31, 2025.
Stated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results Cash : As of June 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $ 20.8 million, compared to $ 17.6 million as of December 31, 2025.” “Current cash, cash equivalents and capital commitments as of March 31, 2026, are expected to fund operations through the first half of 2027.”
“Second Quarter 2026 Financial Results Cash : As of June 30, 2026, Vivani had cash, cash equivalents and restricted cash totaling $ 20.8 million, compared to $ 17.6 million as of December 31, 2025.”
“Current cash, cash equivalents and capital commitments as of March 31, 2026, are expected to fund operations through the first half of 2027.”
Complete and report top-line data from the SLIM-1 Phase 1 trial of NPM-139 semaglutide implant by November 2026 to support advancement to Phase 2 in 2027.
Collaborate with Novo Nordisk under a non-exclusive agreement to evaluate NPM-139 implant technology for chronic weight management.
Over the trailing year it converted -0.74x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 34% of the time over the next year (vs 53% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.